Antibody-Drug Conjugate Drug Market Landscape Report 2026 Featuring 34 Key Players - Past And Emerging Trends, Partnership Opportunities, Drug Pipelines, And Leading Companies

(MENAFN- GlobeNewsWire - Nasdaq) The report identifies key opportunities in Antibody-Drug Conjugates through insights on past trends, drug pipelines, and leading companies. It serves investors, new entrants, and pharma firms looking to prioritize emerging trends and partnership opportunities to gain a competitive edge in this evolving market.

Dublin, Feb. 23, 2026 (GLOBE NEWSWIRE) -- The "Antibody-Drug Conjugate Drug Landscape" report has been added to ResearchAndMarkets's offering.
This report investigates the impacts and development of Antibody-Drug Conjugate therapies within the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern the large-scale changes within the market and how best to pivot to prioritize future changes in the market.
Report Scope

• This 53-page report gives important, expert insight you won't find in any other source. 28 figures throughout the report illustrate major points and trends within the Antibody- Drug Conjugate market delving deep into forecasted sales and company pipelines. This report is required reading for:
• Investors that want to understand past trends impacting the Antibody- Drug Conjugate landscape as well as identifying companies to invest in
• Companies that are interested in entering the Antibody- Drug Conjugate landscape and where best to focus on
• Large pharma companies with investment groups or BD teams looking to see which companies lead the Antibody- Drug Conjugate landscape in the past and how they led
• Small and medium pharma who want to focus their Antibody- Drug Conjugate drug portfolio on future trends and are looking for partnership opportunities

Reasons to Buy

• Insights on the different types of Antibody- Drug Conjugate with current and novel forms
• Insights on past trends and changes that have informed the Antibody- Drug Conjugate market
• Insights on the current leading Antibody- Drug Conjugate drugs based on their Sales and Forecasts and other parameters
• Therapeutic and Indication insights into the Antibody- Drug Conjugate market
• Insights into the future opportunities for Antibody- Drug Conjugate and the companies leading in the market.

Key Topics Covered:
1 Antibody-Drug Conjugate Introduction
1.1 Key milestones timeline
1.2 Total market sales
1.3 Point-in-time counts
2 Antibody-Drug Conjugate: Previous Years in Review
2.1 ADCs by development stage
2.2 Approvals timeline
2.3 Historical sales
2.4 Deals trends
2.5 Patents trends
2.6 Review designation trends
3 Antibody-Drug Conjugate: Current Landscape
3.1 ADCs by development stage
3.2 Top indications
3.3 Top companies
4 Antibody-Drug Conjugate: Future Outlook
4.1 Forecast sales
4.2 Top companies
4.3 Upcoming launches
5 Key Findings
6 Appendix

Companies Featured

• Pfizer
• Seagen
• F. Hoffmann-La Roche Ltd
• Roche Holding AG
• Daiichi-Sankyo Co Ltd
• Abbvie Inc
• Pfizer Inc
• Regeneron Pharmaceuticals Inc
• Gilead Sciences
• Novartis AG
• Bristol Myers Squibb Co
• Astrazeneca Plc
• Sanofi
• Biocytogen Pharmaceutical Co Ltd
• Hangzhou DAC Biotech Co Ltd
• LigaChem Biosciences Inc
• Innovent Biologics Inc
• Shanghai Affinity Biopharmaceutical Co Ltd
• LaNova Medicines Ltd
• Genmab AS
• Jiagsu Hengrui Pharmaceuticals Co Ltd
• Duality Biologics Co Ltd
• BioNTech SE
• Remegen Co Ltd
• CSPC Pharmaceutical Group Ltd
• Zai Lab
• Cytomx Therapeytics Inc
• GSK Plc
• Primelink Biotherapeutics Co Ltd
• Radiopharam Theranostics
• T-E Meds Inc
• Neok Bio Inc
• National Cancer Institute US
• Hutchmed China Ltd

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN23022026004107003653ID1110776196